Trump signs memorandum to restrict investments that do not serve American interests; A Jiangsu court ruled that investments in overseas crypto projects are not protected under Chinese law; and Chinese companies raise funds in hope of easing of regulations against private enterprises
Simon Leung, Partner of Baker McKenzie, and Terry Xu, Senior Counsel at FenXun Partners, examine key regulatory shifts in 2024 and provide an outlook of potential regulatory trends for the banking and finance sector in 2025
Calvin Klein parent PVH investigated by Chinese government after pulling out of Xinjiang; Chinese biotech firms targeted by U.S. BIOSECURE Act seek to sell U.S. subsidiaries; and China promises to protect private business while maintaining the existing economic order is still important.
China allows fully foreign-owned hospitals and foreign investment in gene technologies; China is assessing the compatibility of the international AI agreement with its own strategic plans; and China's Ministry of Finance strengthens its regulation of foreign accounting organizations, particularly for those that do not have offices in China
U.S. lawmakers call on the government to scrutinize drugmakers' clinical trials in China; China removes restrictions for foreign investments in the manufacturing and services industries; and Cross-Boundary Wealth Connect gains 10 new additional securities firms for increased offshore investment opportunities.
Alleged receiving of kickbacks by senior executives in China could subject Adidas to Chinese, as well as German and U.S. investigations; U.S. convertible bond market is used to raise funds by Chinese big tech amid IPO restrictions; and EU tariffs may lead to localization of Chinese EV production.
